Cart
sales@molnova.com
CRAC intermediate 1
CAS No. 1249343-86-9
CRAC intermediate 1( 5-(S)-Fluorowillardiine )
Catalog No. M26129 CAS No. 1249343-86-9
CRAC intermediate 1 is a key intermediate in the chemical synthesis of a series of CRAC channel inhibitors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 31 | In Stock |
|
| 25MG | 59 | In Stock |
|
| 50MG | 91 | In Stock |
|
| 100MG | 138 | In Stock |
|
| 200MG | 206 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCRAC intermediate 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCRAC intermediate 1 is a key intermediate in the chemical synthesis of a series of CRAC channel inhibitors.
-
DescriptionCRAC intermediate 1 is a key intermediate in the chemical synthesis of a series of CRAC channel inhibitors.
-
In Vitro——
-
In Vivo——
-
Synonyms5-(S)-Fluorowillardiine
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorAMPA
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1249343-86-9
-
Formula Weight223.183
-
Molecular FormulaC10H7F2N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 50 mg/mL (224.03 mM)
-
SMILESFc1cccc(F)c1C(=O)Nc1cc[nH]n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Arai AC, Kessler M, Rogers G, Lynch G. Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466. Mol Pharmacol. 2000 Oct;58(4):802-13. PubMed PMID: 10999951.
molnova catalog
related products
-
HUP30
HUP30 is a potent vasodilating agent. HUP30 can stimulate soluble guanylyl cyclase, activate K+ channels, and block extracellular Ca2+ influx.
-
(S)-Amlodipine Besyl...
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive and anti-anginal medication.
-
TTA-Q6
TTA-Q6, a selective T-type Ca2+ channel antagonist, exhibits potential antitumor and immunomodulatory activities for treating neurological disorders by inhibiting the uptake of extracellular calcium ions by tumor cells, thereby inducing intracellular calcium deficiency and endoplasmic reticulum (ER) stress.
